Title: Distinct respiratory tract biological pathways characterizing ARDS molecular
phenotypes

Authors: Aartik Sarma[1], Stephanie A. Christenson[1], Beth Shoshana Zha[1], Angela Oliveira
Pisco[2], Lucile P.A. Neyton[1], Eran Mick[2,3], Pratik Sinha[4], Jennifer G. Wilson[5], Farzad Moazed[1],
Aleksandra Leligdowicz[6,7], Manoj V. Maddali[8], Emily R. Siegel[9], Zoe M. Lyon[9], Hanjing Zhou[1],
Alejandra Jauregui[1], Rajani Ghale[1], Saharai Caldera[2], Paula Hayakawa Serpa[2,3], Thomas
Deiss[1], Christina Love[2], Ashley Byrne[2], Katrina L. Kalantar[2], Joseph L. DeRisi[2], David J.
Erle[6,10,11,12], Matthew F. Krummel[11,13], Kirsten N. Kangelaris[14], Carolyn M. Hendrickson[15],
Prescott G. Woodruff[1,6], COMET Consortium, Michael A. Matthay[1,6,16], Charles R. Langelier[2,3],
Carolyn S. Calfee[1,6,16]

Affiliations:

1.   Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of
Medicine, University of California San Francisco, CA
2.   Chan Zuckerberg Biohub, San Francisco, CA
3.   Division of Infectious Diseases, Department of Medicine, University of California San
Francisco, CA
4.   Department of Anesthesia, Washington University in St Louis
5.   Department of Emergency Medicine, Stanford University School of Medicine, Stanford
University, Stanford, CA
6.   Cardiovascular Research Institute, University of California San Francisco, CA
7.   Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto,
Ontario, Canada
8.   Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
Stanford University, Stanford, CA
9.   School of Medicine, University of California San Francisco, CA
10. Lung Biology Center, University of California San Francisco, CA
11. Bakar ImmunoX Initiative, University of California San Francisco, CA
12. UCSF CoLabs, University of California San Francisco, CA
13. Department of Pathology, University of California San Francisco, CA
14. Division of Hospital Medicine, University of California San Francisco, CA
15. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Zuckerberg
San Francisco General Hospital and Trauma Center, University of California San
Francisco
16. Department of Anesthesia, University of California San Francisco, CA

35
36 Word count: 3,493

Abstract:

Background: Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and responses to therapy have been identified. Classification as "hyperinflammatory" or "hypoinflammatory" depends on plasma biomarker profiling. Differences in pulmonary biology underlying these phenotypes are unknown.

Methods: We analyzed tracheal aspirate (TA) RNA sequencing (RNASeq) data from 41 ARDS patients and 5 mechanically ventilated controls to assess differences in lung inflammation and repair between ARDS phenotypes. In a subset of subjects, we also analyzed plasma proteomic data. We performed single-cell RNA sequencing (scRNASeq) on TA samples from 9 ARDS patients. We conducted differential gene expression and gene set enrichment analyses, *in silico* prediction of pharmacologic treatments, and compared results to experimental models of acute lung injury.

Findings: In bulk RNASeq data, 1334 genes were differentially expressed between ARDS phenotypes (false detection rate < 0.1). Hyperinflammatory ARDS was characterized by an exaggerated innate immune response, increased activation of the integrated stress response, interferon signaling, apoptosis, and T-cell activation. Gene sets from experimental models of lipopolysaccharide lung injury overlapped more strongly with hyperinflammatory than hypoinflammatory ARDS, though overlap in gene expression between experimental and clinical samples was variable. ScRNASeq demonstrated a central role for T-cells in the hyperinflammatory phenotype. Plasma proteomics confirmed a role for innate immune activation, interferon signaling, and T-cell activation in the hyperinflammatory phenotype. Predicted candidate therapeutics for the hyperinflammatory phenotype included imatinib and dexamethasone.

Interpretation: Hyperinflammatory and hypoinflammatory ARDS phenotypes have distinct respiratory tract biology, which could inform targeted therapeutic development.

62   **Funding:** National Institutes of Health; University of California San Francisco ImmunoX

63   CoLabs; Chan Zuckerberg Foundation; Genentech

65   Abstract word count: 246 without funding

Introduction

The acute respiratory distress syndrome (ARDS) is characterized by noncardiogenic pulmonary edema and hypoxemia within one week of a physiologic insult[1]. The global incidence of ARDS has surged during the COVID-19 pandemic, increasing the importance of finding effective treatments. While some pharmacologic interventions have decreased mortality in patients with severe COVID-19[2,3], no drug has consistently reduced mortality in more typical heterogeneous cohorts of patients with ARDS. There is a growing recognition that biological heterogeneity within the syndrome is a significant barrier to identifying effective treatments[4].

Two clinically distinct molecular phenotypes of ARDS (termed "hyperinflammatory" and "hypoinflammatory") have been identified using latent class analysis of clinical and plasma biomarker data in eight cohorts[1,5–11]. The hyperinflammatory phenotype is characterized by elevated plasma inflammatory cytokines (IL-8, IL-6, TNFr-1), lower plasma Protein C and bicarbonate, and higher mortality compared to the hypoinflammatory phenotype. Importantly, significant differences in treatment response to simvastatin, ventilator settings, and fluid management have been observed across molecular phenotypes in retrospective analyses of three ARDS clinical trials[5,6,11]; further, in patients with COVID-19-related ARDS, hyperinflammatory patients may preferentially respond to corticosteroid treatment[12,13]. These results suggest that understanding and targeting the heterogeneous biology underlying ARDS molecular phenotypes is essential to identifying effective new treatments for ARDS. Prospective studies designed to identify these phenotypes using parsimonious models are laying the groundwork for precision clinical trials[4,14].

Despite this exciting progress, a critical barrier to developing new therapies for ARDS is the limited understanding of the biological pathways characterizing each phenotype. This knowledge gap was recently cited by NHLBI and European Respiratory Society workshops on precision medicine in ARDS as a top research priority for the field[4,15]. To date, analyses of the biological differences between these phenotypes have been largely limited to circulating

biomarkers, due to the relative ease of sampling. Understanding the biological differences

between ARDS molecular phenotypes in the lung, the active site of injury, will be critical to

development of informative pre-clinical models of disease and targeted treatments for ARDS.

Here, we employ a systems biology approach incorporating bulk and single-cell RNA-

sequencing, *in silico* analyses, and proteomics to understand differences in lung immunology

and inflammatory responses between ARDS phenotypes.

Methods:

Study subjects

Subjects were enrolled in two prospective observational cohorts of critically ill patients.

We used bulk RNASeq data and plasma proteomic data from the Acute Lung Injury in Critical

Illness (ALI) study, a cohort of mechanically ventilated adults admitted to the intensive care unit

at the University of California, San Francisco Medical Center (UCSFMC) between July 2013 and

March 2020. We used single-cell RNA-Sequencing (scRNASeq) data from the COVID-19

Multiphenotyping for Effective Therapies (COMET) study, a study of hospitalized patients with

COVID-19 or other acute respiratory illnesses admitted to UCSFMC or Zuckerberg San

Francisco General Hospital (ZSFGH). COVID-19 status was confirmed by clinical PCR testing

and metagenomic sequencing. These studies were approved by the UCSF Institutional Review

Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA

and blood samples. Informed consent was then obtained from patients or surrogates, as

previously described[16].

In this analysis, we included all available subjects in each cohort who were admitted to

the intensive care unit for mechanical ventilation for ARDS or for airway protection without

radiographic evidence of underlying pulmonary disease. For non-ARDS control patients in the

ALI study, we excluded subjects on immunosuppression, including corticosteroids, and those

with immunocompromising conditions (e.g., bone marrow transplant recipients).

ARDS adjudication and phenotype assignment

Electronic health records were adjudicated for ARDS (Berlin Definition[17]) by at least two clinicians blinded to all biological data. Lower respiratory tract infections were diagnosed using the CDC surveillance definition[18]. ARDS phenotype was determined using a validated three-variable classifier model (IL-8, protein C, and bicarbonate)[14]. Subjects with a probability of class assignment greater than 0.5 were assigned to the hyperinflammatory phenotype. Plasma biomarkers were not available for five subjects with TA bulk RNA sequencing. For these subjects, we used a validated clinical classifier model to assign phenotype[10,19].

Tracheal aspirate sampling and RNA sequencing

Following enrollment in the ALI cohort, TA was collected within three days of intubation. In the COMET cohort, TA samples were collected daily, and the first available sample collected within three days of enrollment was used for this analysis. For bulk RNA sequencing, TA was collected and stored in DNA/RNA Shield (Zymo, Inc.) at -80C[16]. Samples underwent library preparation and Illumina paired-end sequencing using established methods described in detail in the online supplement. For scRNASeq, TA was collected and processed within 3 hours as previously described[20].

Cell annotation, differential expression, pathway, and network analysis

We performed pairwise comparisons of gene expression in each ARDS phenotype and controls using *DESeq2*. Single cell transcriptomes were annotated using *SingleR*. We compared gene expression between phenotypes for each cell type using *MAST*, using a mixed effects model with fixed effects for phenotype and cellular detection rate and a random effect for subject. Differentially expressed genes were then analyzed using Ingenuity Pathway Analysis (IPA, Qiagen). Full details of cell annotation, differential gene expression, and IPA analyses are

provided in the online supplement. To study how cell-cell signaling contributed to observed

differential expression, we used *CellChat*[21] to infer intercellular communication networks by

comparing scRNASeq data to a curated database of ligands, receptors, and their cofactors.

Plasma proteomic analysis

Plasma samples from the Acute Lung Injury in Critical Illness cohort and 14 healthy

controls from a previously published dataset[22] were analyzed using the O-link Proteomics

Assay, which generates a semi-quantitative measurement of 96 plasma proteins. We excluded

all samples that were flagged with a QC warning from the O-link platform and excluded any

biomarker for which protein concentrations could not be measured for at least 90% of samples.

Measurements for 73 proteins passed the manufacturer's quality control filter and were included

for analysis. Normalized protein expression measurements were compared using a Wilcoxon

rank-sum test and p-values were adjusted using the Benajmini-Hochberg method (FDR < 0.1).

Comparison of differentially expressed genes to experimental models of acute lung

injury

We identified experimental models of acute lung injury in the Gene Expression Omnibus.

Lists of all genes differentially expressed at a Benjamini-Hochberg adjusted p-value less than

0.05 were downloaded using GEO2Enrichr[23]. We then used the genes that were upregulated in

the experimental lung injury model as gene signatures in GSVA[24] (Supplemental Data 3A). If

more than 200 genes were differentially expressed in the experimental model, we used the top

200 genes (by p-value) for the experimental gene signature. We used *limma*[25] to compare

GSVA scores in samples from each phenotype to GSVA scores in controls.

Results

Patient Characteristics: Acute Lung Injury in Critical Illness Cohort

In the Acute Lung Injury in Critical Illness cohort, TA sequencing data was available for

41 ARDS participants and five controls (Figure S1). Ten of 41 ARDS subjects (24%) were

classified as the hyperinflammatory phenotype, consistent with the proportion observed in

previous studies[5–8,11]. There were no significant differences in age, sex, BMI,

immunosuppression, respiratory viral or bacterial infections, or ARDS risk factors between

hyperinflammatory and hypoinflammatory patients (Table 1).

Bulk RNA-Sequencing

1,334 genes were differentially expressed between ARDS phenotypes with an absolute

empirical Bayesian posterior $\log_2$-fold change >0.5 (Figure S2A, Supplementary Data S1A). IPA

predicted increased activation of several cytokines and other upstream regulators of

differentially expressed genes in hyperinflammatory ARDS, compared with hypoinflammatory

ARDS (Figure 1A, Supplementary Data S2A). These included several cytokines classically

associated with an innate response previously found to be elevated in plasma of patients with

hyperinflammatory ARDS, including IL1B, IL6, and TNF. In addition, IPA identified activation of

cytokine responses not previously studied in hyperinflammatory ARDS, including numerous

interferon-stimulated genes; IL2 and IL15, which stimulate cytotoxic T cell and NK cell

responses[26]; and the chemokine ligand CCL2/MCP-1. Upstream regulator analysis predicted

increased activation of transcriptional regulators critical to the integrated stress response

(XBP1, NFE2L2) and increased cellular differentiation (MYC, NONO), as well as stimulation of

Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) and receptors integral to T cell activation

(CD3, CD28) in hyperinflammatory ARDS.

To further understand how pathways in each phenotype were dysregulated, we

compared each phenotype to mechanically ventilated control patients with neurologic injury.

2,989 genes were differentially expressed between hyperinflammatory ARDS and controls

(Figure S2B, Supplementary Data 1C), while 2,132 genes were differentially expressed between

hypoinflammatory ARDS and controls (Figure S2C, Supplementary Data 1D). Notably,

upstream regulator analysis identified several cytokines that were activated in both

hyperinflammatory and hypoinflammatory ARDS compared to controls (Figure 1C,

Supplementary Data 2C and 2D), including IL1B, TNF, and IFNG. While this analysis identified

some similarities between phenotypes, it also confirmed that several upstream regulators that

were activated in pairwise comparisons of hyperinflammatory ARDS to hypoinflammatory ARDS

and hyperinflammatory ARDS to controls, suggesting these upstream regulators play an

important role in the distinct features of hyperinflammatory ARDS. These included IL6, which

was one of plasma cytokines used to define the hyperinflammatory phenotype[5]; IL18, which was

not measured in the original LCA studies, but, like the hyperinflammatory phenotype, was

associated with higher mortality and a response to simvastatin in the HARP-2 trial[27]; the T cell

receptor; Type I/III interferons (IFNA, IFNL, IFNB), indicative of an enhanced mucosal interferon

response[28]; several Toll-like receptors (TLR2/3/9); and FAS, which stimulates apoptosis[29]. In

addition, several upstream regulators associated with specific immune cells were predicted to

be activated in hyperinflammatory ARDS but not in hypoinflammatory ARDS, including markers

of activated T cells (NFATC1[30]), NK cells (NCR1[31], KLRK1[32]), and platelets (PF4[33]), suggesting

these cells play a key role in the distinct biology of hyperinflammatory ARDS.

Alignment with Experimental Models of Lung Injury

IPA identified lipopolysaccharide (LPS), a component of gram-negative bacteria, as an

upstream regulator of genes differentially expressed between ARDS phenotypes

(Supplementary Data S2A) and in comparisons of each ARDS phenotype to controls

(Supplementary Data S2C and S2D). We hypothesized that genes upregulated in LPS models

of lung injury would be more upregulated in hyperinflammatory ARDS compared to controls than

in hypoinflammatory ARDS compared to controls. Respiratory tract gene expression data was

available from four LPS models of ARDS in the Gene Expression Omnibus. We also identified

17 more datasets from other experimental models of ARDS including ventilator-induced lung

injury (VILI), ozone, hyperoxia, Pam3Cys (a TLR2 agonist), and hemorrhagic shock

(Supplementary Data S3A). Gene sets from four models were significantly enriched (FDR < 0.1)

in TA from both ARDS phenotypes (Figure 1B; Supplementary Data S3B and S3C). As

expected, LPS models had a significant overlap with both phenotypes, but LPS experimental

gene sets had higher GSVA scores in hyperinflammatory participants. In addition, gene sets

from two ozone models, two LPS models, and one VILI model were enriched in

hyperinflammatory ARDS but not in hypoinflammatory ARDS, suggesting these models better

replicated dysregulated gene expression observed in the hyperinflammatory phenotype.

***In silico* analysis of candidate drugs for hyperinflammatory ARDS**

To identify candidate treatments for the hyperinflammatory ARDS phenotype, we used

Upstream Regulator Analysis to identify drugs predicted to decrease expression of genes

upregulated in hyperinflammatory ARDS compared to hypoinflammatory ARDS or controls

(Figure 1C). For example, dexamethasone, which decreases interferon-gamma signaling[34], was

predicted to shift gene expression away from hyperinflammatory ARDS. Interestingly, several

drugs which cause drug-induced pneumonitis (e.g., nitrofurantoin, amiodarone, and cytarabine)

were predicted to shift gene expression from controls toward hyperinflammatory ARDS

(Supplementary Data S2C).

Single-cell RNA-sequencing

We used a neutrophil-preserving scRNASeq method to study TA from nine COVID-

negative patients with ARDS enrolled in a separate observational cohort (COMET; described in

Methods). TA scRNASeq was available from five participants with hypoinflammatory ARDS and

four with hyperinflammatory ARDS; clinical characteristics of these patients are provided in

Supplementary Table 1. 26,429 cells passed quality filters, and we used SingleR[35] to identify

cell types (Figure 2A). Neutrophils were the most common cell in both phenotypes (Figure 2B),

CellChat predicted markedly higher interaction between T cells and other cell types in

the hyperinflammatory phenotype (Figure 2C), which was consistent with the bulk analysis

predicting increased T cell activation. Phenotype-specific differences in cell-cell signaling were

driven by ligand-receptor pairs in several pathways (Figure 2D; Supplementary Figure 6A and

6B). In the hyperinflammatory phenotype, *CellChat* predicted increased MHC-I signaling, which

was driven by increased signaling to CD8 on T cells and NK cells. In contrast, MHC-II activity

was predicted to be higher in hypoinflammatory ARDS. *CellChat* also identified increased

NAMPT signaling by NK and T cells to integrin ☐5β1 on monocytes, macrophages, and

dendritic cells in hyperinflammatory ARDS (Supplementary Data 6). Notably, NAMPT

polymorphisms are associated with a 7.7-fold increased risk of sepsis-associated ARDS[36] and

NAMPT was identified as an upstream regulator of differential gene expression in our bulk

RNASeq data (Figure 1C). These results further supported the hypothesis that there are marked

differences in respiratory tract signaling between phenotypes driven by differences in T and NK

cell signaling.

We next used *MAST* to compare differential gene expression in TA neutrophils, T cells,

monocyte-derived macrophages, and monocytes (Supplementary Figure 4, Supplementary

Data S4). We used IPA to identify upstream regulators of gene expression and analysis

identified several cell-specific differences in gene expression (Figure 2E, Supplementary Data

S5). Notably, some cytokines that were predicted to be activated in hyperinflammatory ARDS in

the bulk RNA sequencing data, including TNF and IFNG, were relatively less active in

neutrophils and monocytes from hyperinflammatory TA samples. In contrast, interferon lambda,

which is produced by the respiratory epithelium, was predicted to be more activated in

hyperinflammatory neutrophils and T cells. IPA also predicted increased activation of cell

activation of the integrated stress response (XBP1, EIF2AK2) and TLR4 in T cells from the

hyperinflammatory phenotype (Supplementary Data S5D).

Plasma proteomic analysis identifies additional cytokines upregulated in

hyperinflammatory ARDS

To further validate the biologic relevance of the TA findings, we measured plasma

concentrations of 96 protein biomarkers. 21 participants included in the TA bulk sequencing

analysis had protein biomarker data available, as did four participants from the same cohort who

did not have TA bulk sequencing available. Of these 25 participants, five had hyperinflammatory

ARDS and 20 had hypoinflammatory ARDS (Supplementary Table 2). We compared these

subjects to 14 healthy controls (mean age: 38, 43% female) and included in a previously

published analysis[22].

Plasma concentrations of 28 proteins were higher in hyperinflammatory ARDS than in

hypoinflammatory ARDS (FDR < 0.1, Figure 3A). Some of these biomarkers confirmed known

differences between phenotypes, including higher concentrations of IL6 and TNF in

hyperinflammatory ARDS. Nine of these biomarkers were also elevated in hyperinflammatory

ARDS compared to controls but were not elevated in hypoinflammatory ARDS (Figure 3B and

3C), suggesting they identify distinctly dysregulated pathways in the hyperinflammatory

phenotype. These proteins included IL-8, which is one of the cytokines that defines the

hyperinflammatory phenotype; CASP-8, an effector of FAS signaling[37]; interferon-induced

proteins CXCL9 and CXCL10[38]; plasma urokinase (uPA); oncostatin M; and adenosine

deaminase (ADA). In addition, CCL2/MCP-1 and the T cell activation marker CD5[39] were higher

in hyperinflammatory ARDS and in controls compared to hypoinflammatory ARDS. These

observations were consistent with differences in TA gene expression at both the bulk RNASeq

and scRNASeq level. Plasma proteins that were higher in controls than in ARDS subjects are

shown in Supplementary Figure S7.

Discussion

This analysis represents the first report of significant differences in pulmonary biology between ARDS molecular phenotypes, which have previously been characterized primarily using plasma biomarkers. In addition to confirming evidence of innate immune activation suggested by prior data on circulating plasma biomarkers, these analyses identify several novel pathways as relevant to the pathogenesis of hyperinflammatory ARDS, including interferon-stimulated pathways, apoptosis, and T-cell signaling, and suggest that each ARDS phenotype has distinct pulmonary pathobiology which could help identify new therapeutic targets.

We identified a central role of T and NK cells in coordinating dysregulated inflammation in hyperinflammatory ARDS. Hyperinflammatory ARDS was associated with markedly higher mucosal interferon-stimulated gene expression and T/NK cell activation in bulk sequencing of TA. Network analysis of scRNASeq data was also consistent with a central role of T and NK cells in hyperinflammatory ARDS. These analyses identified differences in APC to T/NK cell signaling, with greater MHC-I to CD8 signaling in the hyperinflammatory phenotype. Single cell differential expression also predicted increased activation of TLR4 and XBP1 in hyperinflammatory ARDS, suggesting the integrated stress and innate immune responses are upregulated in T cells from the hyperinflammatory phenotype. In contrast to prior literature on ARDS[40,41], which has emphasized the role of neutrophils, activated macrophages, and alveolar epithelial cells in ARDS pathogenesis, our observations suggest lymphocytes play an underrecognized role in coordinating dysregulated inflammation in hyperinflammatory ARDS.

Some features that characterized the hyperinflammatory phenotype in bulk sequencing (e.g., higher predicted activation of cytokines classically associated with an innate response) were not observed in specific cell types in scRNASeq. This observation has several possible explanations. First, the results in bulk RNA sequencing may be driven by differences in the immune cell composition of TA in each phenotype, as suggested by our scRNASeq analyses.

Notably, a similar pattern of high interferon-stimulated gene expression in T cells but diminished

immune responses in macrophages has also been reported in severe COVID-19[42]. Second, the

bulk signals may be driven by highly activated cells that do not survive the scRNASeq

processing pipeline, as has been reported previously for activated macrophages and

neutrophils. Third, some signals observed in the bulk data may be driven by epithelial cells,

which were selected against in our scRNASeq pipeline (in favor of enriching for immune cell

populations) and are thus not well-represented.

Plasma proteomics identified increased concentrations of the interferon-stimulated

proteins CXCL9 and CXCL10 and the T cell activation marker CD5 in hyperinflammatory ARDS

but not in hypoinflammatory ARDS. Notably, in an alternative molecular phenotyping approach

that used *k*-means clustering of plasma biomarkers to categorize ARDS subjects into two

molecular phenotypes ("reactive" and "uninflamed"), plasma IFNγ is one of the defining

biomarkers of the higher mortality "reactive" phenotype[43]. Taken together, these analyses

support a central role of mucosal interferons and T cell activation in hyperinflammatory ARDS.

To our knowledge, only one prior study has attempted to characterize the pulmonary

compartment in ARDS phenotypes[44]. This study included 10 hypoinflammatory patients and 16

hyperinflammatory patients and found no difference between these groups in concentration of

several inflammatory protein biomarkers in mini-BAL samples or in the lung microbiome. Our

results may differ from these because of a larger sample size, differing analytic approaches,

differing sampling strategies, or some combination thereof.

We compared differentially expressed genes in clinical samples to experimental ARDS

models to determine the relevance of these models to each phenotype. An experimental model

combining intratracheal LPS *and* mechanical ventilation was the murine model with the

strongest overlap in gene expression with ARDS subjects in both phenotypes. This gene

signature was from an experiment demonstrating that a combined MV/LPS model generated

markedly higher neutrophilic inflammation in the lung than LPS or MV alone[45]. In addition, gene

signatures from five LPS models were enriched in hyperinflammatory ARDS but were not

enriched in hypoinflammatory ARDS, suggesting that hypoinflammatory patients, on average,

have less of an overlap in respiratory biology with the preclinical models. Our results also

indicate that the overlap in gene expression between experimental models and clinical samples

is highly variable, even among models with similar injurious stimuli (e.g., among VILI models).

Further study is required to understand how best to model each phenotype experimentally and if

our observations partially explain why therapies that appear promising in pre-clinical models are

not effective in more heterogeneous clinical trial populations.

Our results have important implications for developing a precision approach to treating

ARDS[4]. The *in silico* analysis identified several candidate therapies that target the dysregulated

pathways identified in hyperinflammatory ARDS. Several of the candidate drugs, including

imatinib, dexamethasone, and metformin, decrease lung injury caused by LPS in experimental

models[46–48], again suggesting LPS replicates important features of the hyperinflammatory

phenotype. Approximately one-third of candidate drugs identified using pathway analyses are

validated in *in* vivo[49] and these treatments require validation in further preclinical studies and

clinical trials.

Strengths of this study include transcriptomic analysis of samples from the focal organ of

injury in ARDS, providing a detailed picture of the pulmonary biology of both ARDS phenotypes,

and deepening of these observations with single-cell sequencing and peripheral blood

proteomics. The inclusion of non-ARDS ventilated controls allowed us to further characterize the

physiologic dysregulation in the phenotypes, rather than defining gene expression relative to

another pathologic state. This analysis also has some limitations. Bulk and single-cell RNASeq

samples were collected in separate cohorts, so we cannot integrate these analytical

approaches. Although TA contains fluid from the distal airspaces[50], more invasive BAL testing

may identify additional differences between the phenotypes.

In conclusion, an integrated, multi-omic analysis of ARDS molecular phenotypes

originally defined by clinical and plasma protein biomarkers suggests the hyperinflammatory

phenotype is characterized by increased interferon-stimulated gene expression coordinated by

T cell signaling in the lower respiratory tract. Our findings suggest that the respiratory tract

biology of these phenotypes is distinct and further supports the use of molecular phenotypes to

study acute lung injury biology and develop new treatments for ARDS.

Materials and Methods

List of Supplementary Materials

Figure S1: Subjects included in this analysis.

Figure S2: Volcano plots showing differential gene expression between (A) 10

hyperinflammatory ARDS and 31 hypoinflammatory ARDS subjects, (B) 10 hyperinflammatory

ARDS and 5 control subjects, and (C) 31 hypoinflammatory ARDS and 5 control subjects.

Figure S3: GSVA scores for signatures of ALI experimental models in TA transcriptomes from 5

control subjects, 31 hypoinflammatory ARDS subjects, and 10 hyperinflammatory ARDS

subjects.

Figure S4: Volcano plots showing differential gene expression in scRNASeq for 5

hypoinflammatory ARDS subjects and 4 hypoinflammatory ARDS subjects in the COMET

cohort.

Figure S5: Circos plots displaying differentially interactive ligand-receptor pairs identified by

CellChat in a comparison of scRNASeq from 5 hypoinflammatory and 4 hyperinflammatory

ARDS subjects. (A) Pairs that are relatively higher in hyperinflammatory ARDS and (B) Pairs

that are relatively higher in hypoinflammatory ARDS.

Figure S6: Heatmaps for plasma proteins that are significantly higher in (A) Controls vs.

hyperinflammatory ARDS and (B) Controls vs. hypoinflammatory ARDS

Figure S7: Heatmap showing estimated power to detect a difference between phenotypes in

the Acute Lung Injury in Critical Illness cohort based on effect size and within-group coefficient

of variation.

Supplementary Data S1: Differential gene expression for pairwise comparisons of bulk RNA

gene expression for TA in the Acute Lung Injury in Critical Illness cohort. A positive $\log_2$ fold

difference indicates the gene is more highly expressed in the first group compared to second

group for each comparison. (A) Hyperinflammatory ARDS vs. hypoinflammatory ARDS; (B)

Hyperinflammatory ARDS vs. hypoinflammatory ARDS after adjusting for fungal infections; (C)

Hyperinflammatory ARDS vs. controls; and (D) Hypoinflammatory ARDS vs. controls; and (E)

All ARDS subjects vs. controls.

Supplementary Data S2: IPA Upstream Regulator scores for pairwise comparisons of bulk

RNA gene expression for TA in the Acute Lung Injury in Critical Illness Cohort. A positive z-

score indicates gene expression is consistent with higher activity of the upstream regulator in

the first group compared to second group for each comparison. (A) Hyperinflammatory ARDS

vs. hypoinflammatory ARDS; (B) Hyperinflammatory ARDS vs. controls; (C) Hypoinflammatory

ARDS vs. controls; and (D) All ARDS vs. controls.

Supplementary Data S3: (A) 200 most upregulated genes in experimental models of lung injury

compared to controls for 21 experimental systems in the Gene Expression Omnibus. (B) Gene

set enrichment analysis scores and leading-edge genes for experimental model gene sets in TA

differential expression for hyperinflammatory ARDS vs. controls. (C) Gene set enrichment

analysis scores and leading-edge genes for experimental model gene sets in TA differential

expression for hypoinflammatory ARDS vs. controls.

Supplementary Data S4: Differential gene expression for single-cell RNA sequencing for TA

for the COMET cohort. A positive $\log_2$ fold difference indicates the gene is more highly

expressed in hyperinflammatory ARDS. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived

macrophages, (D) T cells

Supplementary Data S5: IPA Upstream Regulator scores for pairwise comparisons of bulk

RNA gene expression for TA in the COMET. A positive z-score indicates gene expression is

consistent with higher activity of the upstream regulator in the hyperinflammatory ARDS

samples. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived macrophages, (D) T cells

Supplementary Data S6: CellChat results for ligand-receptor pairs in TA scRNASeq from the

COMET cohort for (A) hyperinflammatory ARDS and (B) hypoinflammatory ARDS.

Supplementary Data S7: (A) Z-scaled O-link protein concentrations for five hyperinflammatory

ARDS, 20 hypoinflammatory ARDS, and 14 control subjects. (B) Results of Wilcoxon rank-sum

tests for pairwise comparisons of hyperinflammatory ARDS, hypoinflammatory ARDS, and

control subjects.

References

Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nature Reviews Disease Primers* 2019; **5**: 1–22.

RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine* 2021; **384**: 693–704.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; **397**: 1637–45.

Beitler JR, Thompson BT, Baron RM, *et al.* Advancing precision medicine for acute respiratory distress syndrome. *Lancet Respir Med* 2021; : S2213-2600(21)00157-0.

Calfee CS, Delucchi K, Parsons PE, *et al.* Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. *The Lancet Respiratory Medicine* 2014; **2**: 611–20.

Famous KR, Delucchi K, Ware LB, *et al.* Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. *American Journal of Respiratory and Critical Care Medicine* 2017; **195**: 331 338.

Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Medicine* 2018; **44**: 1859–69.

Sinha P, Delucchi KL, Chen Y, *et al.* Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study. *Thorax* 2021; published online July 5. DOI:10.1136/thoraxjnl-2021-217158.

Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. *The Lancet* 2021; **398**: 622–37.

Maddali MV, Churpek M, Pham T, *et al.* Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. *Lancet Respir Med* 2022; **10**: 367–77.

Calfee CS, Delucchi KL, Sinha P, *et al.* Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med* 2018; **6**: 691–8.

Sinha P, Furfaro D, Cummings MJ, *et al.* Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. *Am J Respir Crit Care Med* 2021; **204**: 1274–85.

Chen H, Xie J, Su N, *et al.* Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest* 2021; **159**: 1793–802.

14 Sinha P, Delucchi KL, McAuley DF, O'Kane CM, Matthay MA, Calfee CS. Development and
validation of parsimonious algorithms to classify acute respiratory distress syndrome
phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 2020;
8: 247–57.

15 Bos LDJ, Artigas A, Constantin J-M, *et al.* Precision medicine in acute respiratory distress
syndrome: workshop report and recommendations for future research. *European Respiratory*
Review 2021; **30**. DOI:10.1183/16000617.0317-2020.

16 Langelier C, Kalantar KL, Moazed F, *et al.* Integrating host response and unbiased microbe
detection for lower respiratory tract infection diagnosis in critically ill adults. *Proceedings of*
the National Academy of Sciences 2018; **115**: E12353 E12362.

17 ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. *JAMA*
2012; **307**: 2526–33.

18 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–
associated infection and criteria for specific types of infections in the acute care setting.
American Journal of Infection Control 2008; **36**: 309–32.

19 Sinha P, Churpek MM, Calfee CS. Machine Learning Classifier Models Can Identify Acute
Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. *Am J*
Respir Crit Care Med 2020; **202**: 996–1004.

20 Tsitsiklis A, Zha B, Byrne A, *et al.* Impaired immune signaling and changes in the lung
microbiome precede secondary bacterial pneumonia in COVID-19. *Res Sq* 2021; published
online April 23. DOI:10.21203/rs.3.rs-380803/v1.

21 Jin S, Guerrero-Juarez CF, Zhang L, *et al.* Inference and analysis of cell-cell communication
using CellChat. *Nat Commun* 2021; **12**: 1088.

22 Combes AJ, Courau T, Kuhn NF, *et al.* Global absence and targeting of protective immune
states in severe COVID-19. *Nature* 2021; **591**: 124–30.

23 Gundersen GW, Jones MR, Rouillard AD, *et al.* GEO2Enrichr: browser extension and server
app to extract gene sets from GEO and analyze them for biological functions. *Bioinformatics*
2015; **31**: 3060–2.

24 Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and
RNA-Seq data. *BMC Bioinformatics* 2013; **14**: 7.

25 Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-
sequencing and microarray studies. *Nucleic Acids Research* 2015; **43**: e47.

26 Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy
and vaccine design. *Nat Rev Immunol* 2006; **6**: 595–601.

27 Boyle AJ, Ferris P, Bradbury I, *et al.* Baseline plasma IL-18 may predict simvastatin treatment
response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical
trial. *Crit Care* 2022; **26**: 164.

28 Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III Interferons at
Respiratory and Intestinal Barrier Surfaces. *Frontiers in Immunology* 2020; **11**.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.608645 (accessed Dec 7, 2022).

29 Caulfield AJ, Lathem WW. Disruption of Fas-Fas Ligand Signaling, Apoptosis, and Innate
Immunity by Bacterial Pathogens. *PLOS Pathogens* 2014; **10**: e1004252.

30 Lee J-U, Kim L-K, Choi J-M. Revisiting the Concept of Targeting NFAT to Control T Cell
Immunity and Autoimmune Diseases. *Frontiers in Immunology* 2018; **9**.
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02747 (accessed Dec 7, 2022).

31 Walzer T, Bléry M, Chaix J, *et al.* Identification, activation, and selective in vivo ablation of
mouse NK cells via NKp46. *Proceedings of the National Academy of Sciences* 2007; **104**:
3384–9.

32 Bauer S, Groh V, Wu J, *et al.* Activation of NK Cells and T Cells by NKG2D, a Receptor for
Stress-Inducible MICA. *Science* 1999; **285**: 727–9.

33 Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and
inflammation. *Nat Immunol* 2013; **14**: 768–70.

34 Hu X, Li W-P, Meng C, Ivashkiv LB. Inhibition of IFN-γ Signaling by Glucocorticoids1. *The*
Journal of Immunology 2003; **170**: 4833–9.

35 Aran D, Looney AP, Liu L, *et al.* Reference-based analysis of lung single-cell sequencing
reveals a transitional profibrotic macrophage. *Nat Immunol* 2019; **20**: 163–72.

36 Ye SQ, Simon BA, Maloney JP, *et al.* Pre–B-Cell Colony-enhancing Factor as a Potential
Novel Biomarker in Acute Lung Injury. *Am J Respir Crit Care Med* 2005; **171**: 361–70.

37 Muzio M, Chinnaiyan AM, Kischkel FC, *et al.* FLICE, A Novel FADD-Homologous ICE/CED-
3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex.
Cell 1996; **85**: 817–27.

38 Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC
chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse
RENCA tumor. *J Immunol* 1998; **161**: 927–32.

39 Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 Expression Is
Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity. *Journal of*
Experimental Medicine 1998; **188**: 2301–11.

40 Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and
phenotypes. *The Lancet* 2022; **400**: 1145–56.

41 Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nat*
Rev Dis Primers 2019; **5**: 1–22.

42 Yao C, Bora SA, Parimon T, *et al.* Cell-Type-Specific Immune Dysregulation in Severely Ill
COVID-19 Patients. *Cell Reports* 2021; **34**: 108590.

43 Bos LD, Schouten LR, van Vught LA, *et al.* Identification and validation of distinct biological
phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax*
2017; **72**: 876–83.

44 Heijnen NFL, Hagens LA, Smit MR, *et al.* Biological subphenotypes of acute respiratory
distress syndrome may not reflect differences in alveolar inflammation. *Physiological Reports*
2021; **9**: e14693.

45 Altemeier WA, Matute-Bello G, Gharib SA, Glenny RW, Martin TR, Liles WC. Modulation of
Lipopolysaccharide-Induced Gene Transcription and Promotion of Lung Injury by Mechanical
Ventilation. *The Journal of Immunology* 2005; **175**: 3369–76.

46 Stephens RS, Johnston L, Servinsky L, Kim BS, Damarla M. The tyrosine kinase inhibitor
imatinib prevents lung injury and death after intravenous LPS in mice. *Physiol Rep* 2015; **3**:
e12589.

47 Yang J-W, Mao B, Tao R-J, *et al.* Corticosteroids alleviate lipopolysaccharide-induced
inflammation and lung injury via inhibiting NLRP3-inflammasome activation. *Journal of
Cellular and Molecular Medicine* 2020; **24**: 12716–25.

48 Zhang Y, Zhang H, Li S, Huang K, Jiang L, Wang Y. Metformin Alleviates LPS-Induced Acute
Lung Injury by Regulating the SIRT1/NF-κB/NLRP3 Pathway and Inhibiting Endothelial Cell
Pyroptosis. *Front Pharmacol* 2022; **13**: 801337.

49 Felciano RM, Bavari S, Richards DR, *et al.* Predictive systems biology approach to broad-
spectrum, host-directed drug target discovery in infectious diseases. *Pac Symp Biocomput*
2013; : 17–28.

50 Bernhard W, Haagsman HP, Tschernig T, *et al.* Conductive airway surfactant: surface-
tension function, biochemical composition, and possible alveolar origin. *Am J Respir Cell Mol
Biol* 1997; **17**: 41–50.

Acknowledgments:

Funding:
National Institutes of Health grant F32HL151117 (AS)
National Institutes of Health grant R35HL140026 (CSC)
National Institutes of Health grant 2R24AA019661-06A1 (CSC)
National Institutes of Health grant K23HL138461-01A1 (CRL)
National Institutes of Health grant U19AI1077439 (DJE, CSC)
University of California San Francisco ImmunoX CoLabs
Chan Zuckerberg Foundation 2019-202665
Genentech TSK-020586
589
590   **Author contributions**:
591   Conceptualization: AS, SAC, CSC
592   Formal analysis/software: AS, SAC, AOP, LPAN, EM, MVM, AB, KLK
593   Data curation: HZ, AJ, RG, SC, TD
594   Investigation: AS, BSZ, PS, JGW, FM, AL, ERS, ZML, RG, SC, PHS, TD, CL, KNK,
595   CMH, MAM, CRL, CSC
596   Visualization: AS
597   Funding acquisition: AS, CRL, DJE, CSC
598   Project administration: JLD, DJE, MFK, KNK, CMH, PGW, MAM, CRL, CSC
599   Supervision: SAC, CRL, CSC
600   Writing – original draft: AS
601   Writing – review & editing: All authors
602
603   **Competing interests:** Authors declare that they have no competing interests.
604
605   **Data and materials availability:**
606   Code for differential expression and scRNASeq analyses is available at
607   https://github.com/AartikSarma/ARDSPhenotypes
608
The processed gene count data are available from the National Center for Biotechnology
Information Gene Expression Omnibus database under accession code GSE200849. The raw
sequencing data used in this analysis are protected due to data privacy restrictions from the IRB
protocols governing patient enrollment in this study, which protect the release of raw genetic
sequencing data from those patients enrolled under a waiver of consent. Researchers who wish
to obtain raw FASTQ files for the purposes of independently generating gene counts can
contact the corresponding author (aartik.sarma@ucsf.edu) to be added to the IRB protocols and
sign a materials transfer agreement from UCSF ensuring that the data will be securely stored
and only utilized for transcriptomic analyses.

Figure 1: **Bulk RNA sequencing analyses of TA collected in the Acute Lung Injury in Critical Illness**

cohort. (A) Upstream regulator z-scores based on IPA analysis of differential gene expression in pairwise

comparisons of tracheal aspirate bulk RNA sequencing in hyperinflammatory ARDS (N=10), hypoinflammatory

ARDS (N=31), and mechanically ventilated controls (N=5). A positive z-score indicates differential gene

expression is consistent with greater activation of the upstream regulator of gene expression in the first group

in each pairwise comparison. Circles identify upstream regulators that are statistically significant. **(B)** Gene set

variation analysis for experimental models of lung injury. GSVA scores were calculated for each sample, and

the difference between hyperinflammatory ARDS and controls (orange) and hypoinflammatory ARDS and

controls (blue) was estimated with limma. For each model, the GEO Accession Number, organism, and lung

injury model are listed on the x-axis. (**C**) Upstream regulator scores for selected drugs in the IPA database that

are predicted to significantly shift gene expression away from hyperinflammatory ARDS in independent

analyses of differential gene expression with hypoinflammatory ARDS (blue) or controls (green).

Figure 2: TA single-cell RNA sequencing. (A) Seurat UMAP projection of 26,429 TA cell transcriptomes

from four participants with hyperinflammatory ARDS and five participants with hypoinflammatory ARDS,

annotated with cell type as predicted by SingleR. **(B)** UMAP projection of TA cells transcriptomes separated by

ARDS phenotype. **(C)** Differential interaction between cell types predicted by CellChat. Red arrows identify cell

pairs with greater strength of interaction in hyperinflammatory ARDS. **(D)** Differences in strength of ligand-

receptor interaction for pathways in the CellChat database. **(E)** Upstream regulator analysis z-scores for

differentially expressed genes in neutrophils, monocytes, monocyte-derived macrophages, and T cells. A

positive z-score indicates the upstream regulator is predicted to be more highly activated in hyperinflammatory

ARDS. Circles identify upstream regulators that were statistically significant.

Figure 3: **O-Link proteomics results for plasma biomarkers from 5 hyperinflammatory ARDS, 20**

hypoinflammatory ARDS, and 14 control participants. Each heatmap shows plasma protein biomarkers

that were significantly different between groups (FDR < 0.1); for a complete list of proteins, see Supplementary

Data S7. Each column represents an individual subject, and each row shows the z-scaled concentrations.

Rows and columns are clustered using the Euclidean distance. Columns are annotated by phenotype. Z-score

for expression is shown on the color bar on the right. **(A)** Hyperinflammatory ARDS vs. hypoinflammatory

45   ARDS (*: proteins that higher in hyperinflammatory ARDS vs. volunteers but not difference between

46   hypoinflammatory ARDS and controls; ‡: proteins that are higher in hyperinflammatory ARDS vs. volunteers

47   and lower in hypoinflammatory ARDS vs. volunteers) **(B)** Hyperinflammatory ARDS vs. healthy volunteers. **(C)**

48   Hypoinflammatory ARDS vs. healthy volunteers.

	Hyperinflammatory	Hypoinflammatory	P (1)	Control	P (2)	P (3)
N	10	31		5		
Age	66 [56, 72]	63 [51, 70]	0.63	66 ± 23	0.85	0.42
Female	4 (40)	21 (68)	0.95	3 (60)	0.26	0.49
BMI (kg/m^2)	25.0 [23.6, 25.6]	25.9 [23.9, 32.2]	0.27	25.7 ± 4.8	0.24	0.23
Vasopressors at enrollment	9 (90)	19 (61)	0.19	1 (20)	<0.01	0.21
Minimum PF ratio (mmHg)	76 [62, 97]	93 [67, 138]	0.25	296 [216,366]	<0.01	<0.01
SOFA score at enrollment	18 [16, 19]	9 [7, 11]	<0.01	5 [4, 5]	<0.01	<0.01
IL-8, pg/ml	424 [228, 1068]	15 [9, 25]	<0.01	10 [8, 11]	<0.01	0.21
Protein C, % control	51 [31, 62]	103 [76, 132]	<0.01	115 [79, 148]	<0.01	0.76
Immunosuppression	4 (40)	6 (19)	0.37			
Primary ALI Risk Factor			0.79			
Pneumonia	4 (40)	16 (48)				
Sepsis	4 (40)	7 (23)				
Aspiration	2 (20)	6 (23)				
Pancreatitis	0 (0)	1 (3)				
None	0 (0)	1 (3)				
Clinical respiratory microbiology						
Respiratory viral pathogen	1 (10)	1 (3)	0.98			
Respiratory bacterial pathogen	3 (30)	11 (36)	1.00			

Table 1: Characteristics of patients included in differential expression analysis of ARDS phenotypes from the Acute Lung Injury in

Critical Illness cohort. Normally distributed values are reported as mean ± SD. Non-normally distributed values are reported as

median [IQR]. Categorical data are reported as N (% of total for category). P-values are for a t-test for normally distributed

continuous data, Wilcoxon rank-sum for non-normally distributed, and chi-square test for categorical data. P values are for (1)

hyperinflammatory ARDS vs. hypoinflammatory ARDS; (2) hyperinflammatory ARDS vs. controls; (3) hypoinflammatory ARDS vs.

controls